Key Takeaways
- PCOS is being renamed polyendocrine metabolic ovarian syndrome (PMOS) because the original name is misleading and does not reflect the condition’s broader hormonal and metabolic impact.
- PMOS is a lifelong endocrine disorder characterized by androgen excess, insulin resistance, and disrupted follicle development, but cysts are not actually present in the ovaries.
- Diagnosis follows the Rotterdam Consensus: at least two of three features—hyperandrogenism (clinical or biochemical), ovulatory dysfunction, and polycystic‑appearing ovaries—are required.
- The condition affects an estimated 10‑13 % of women of reproductive age, with up to 70 % unaware they have it; prevalence varies geographically, being higher in South Asia and lower in Northern Europe.
- Health consequences extend beyond fertility, increasing risks for type 2 diabetes, hypertension, dyslipidaemia, endometrial cancer, cardiovascular disease, obesity, sleep apnoea, and mental‑health disorders such as depression and anxiety.
- Management is individualized: lifestyle modification, hormonal contraceptives, ovulation‑inducing agents, insulin‑sensitising drugs, and emerging weight‑loss medications are used according to the patient’s priorities (fertility, metabolic health, symptom control).
- The name change to PMOS aims to emphasize the syndrome’s endocrine nature, its metabolic components, and the need for a holistic, lifelong approach to care.
What Is PCOS/PMOS?
Polycystic ovary syndrome, now referred to as polyendocrine metabolic ovarian syndrome (PMOS), is a multifaceted endocrine disorder that typically begins in late adolescence. Symptoms vary among women but commonly include irregular or absent periods, irregular ovulation, excess facial or body hair, acne, weight gain, and scalp hair loss. As Professor Colin Duncan of the MRC Centre for Reproductive Health explains, the presentation can shift across life stages, making the condition highly individualized.
Why the Original Name Is Misleading
The term “polycystic ovary syndrome” suggests the presence of cysts within the ovaries, which is inaccurate. Early observers noted multiple small fluid‑filled sacs and mistakenly labeled them cysts; these structures are actually follicles that house eggs. In a healthy ovary, several follicles begin to develop each month, with one maturing and releasing an egg while the others regress. In PMOS, follicular development often stalls, preventing ovulation despite the absence of true cysts.
Underlying Causes of PMOS
A central feature of PMOS is ovarian overproduction of androgens (“male” sex hormones). This excess stems from an imbalance between follicle‑stimulating hormone (FSH) and luteinising hormone (LH), though the precise trigger for this hormonal dysregulation remains under investigation. Insulin resistance frequently exacerbates androgen excess: heightened insulin stimulates ovarian androgen production, and elevated androgens, in turn, worsen insulin resistance, creating a vicious cycle. Additional contributors include excess body weight—which lowers a protein that clears androgens—and genetic predisposition, with familial clustering indicating multiple genes are involved. Prenatal androgen exposure may also influence risk, suggesting a blend of genetic, environmental, and developmental factors.
How PMOS Is Diagnosed
Clinical diagnosis relies on the Rotterdam Consensus, which requires at least two of three criteria: (1) clinical or biochemical signs of hyperandrogenism (e.g., hirsutism, acne), (2) ovulatory dysfunction manifesting as irregular or absent periods, and (3) polycystic‑appearing ovaries on ultrasound. Notably, a woman can meet the diagnosis without visible ovarian follicles or without menstrual irregularity, underscoring the syndrome’s heterogeneity.
Epidemiology and Awareness
The World Health Organization estimates that PMOS affects 10‑13 % of women of reproductive age. Despite its prevalence, up to 70 % of affected individuals remain undiagnosed. Geographic variation exists, with higher reported rates in South Asia and lower rates in Northern Europe, reflecting differences in genetics, lifestyle, and healthcare access.
Health Implications Beyond Fertility
While irregular ovulation makes PMOS a leading cause of female infertility, its impact extends far beyond reproductive potential. The syndrome elevates risk for metabolic complications such as type 2 diabetes, hypertension, and dyslipidaemia, which together increase cardiovascular disease likelihood. Endometrial cancer risk is also heightened due to unopposed estrogen exposure from chronic anovulation. Obesity frequently co‑occurs and worsens symptoms; women with PMOS tend to expend fewer calories after eating, making weight loss especially challenging. This metabolic struggle contributes to a higher incidence of eating disorders. Mental health is similarly affected, with increased prevalence of depression and anxiety among those living with PMOS.
Management Strategies
There is no cure for PMOS; management is lifelong and tailored to the predominant concerns at any given time. Hormonal contraceptives can regulate menstruation and suppress androgen production, alleviating hirsutism and acne. For those seeking pregnancy, ovulation‑inducing agents such as clomiphene citrate or letrozole are employed. Insulin‑sensitising medications (e.g., metformin) address metabolic dysfunction, while newer weight‑loss pharmacotherapies under trial show promise for mitigating obesity‑related complications. Lifestyle interventions—balanced nutrition, regular physical activity, and weight management—remain foundational, with multidisciplinary care often involving endocrinologists, gynecologists, dietitians, and mental‑health professionals.
Rationale for Renaming to PMOS
The shift from PCOS to polyendocrine metabolic ovarian syndrome addresses two core misconceptions. First, the condition does not involve ovarian cysts, rendering “polycystic” inaccurate. Second, the original name overly focuses on the ovary, neglecting the syndrome’s broad endocrine and metabolic manifestations that affect multiple organ systems. Surveys led by Professor Helena Teede revealed strong support among clinicians and patients for a name that better captures the disorder’s complexity. The new term emphasizes the endocrine nature of the disease, its metabolic repercussions, and its lifelong, systemic impact, aiming to improve understanding, reduce stigma, and encourage comprehensive care.